500+ Tylenol suits revived: $10B risk for Kenvue and OTC pharma

For biopharma executives and investors, the revival of over 500 Tylenol lawsuits strikes at the heart of a $3 billion global acetaminophen market. Even without a definitive causal link, the ruling forces Kenvue to confront a legal overhang that could mirror the opioid and talc litigations—threatening revenue, labeling practices, and R&D priorities for the entire OTC analgesic category.

On July 14, 2026, the 2nd U.S. Circuit Court of Appeals in Manhattan revived more than 500 private lawsuits alleging that prenatal use of Tylenol (acetaminophen) causes autism and ADHD in children. The ruling overturns a December 2024 dismissal by U.S. District Judge Denise Cote, who had excluded three expert witnesses for the plaintiffs on the grounds that their scientific methodology was unreliable. The appeals court did not rule on the merits of the causation claims but held that the expert opinions were based on acceptable scientific interpretations, writing that the analyses 'constitute acceptable interpretations of scientific evidence where scientists may, and in fact do, disagree.' This decision sends the mass tort back to the trial court, where the admissibility of expert testimony will be re-evaluated under the Daubert standard.

“

The consolidated multidistrict litigation names Kenvue—the Johnson & Johnson spinoff that now owns the Tylenol brand—as well as major retailers including CVS, Kroger, Target, Walgreens, and Walmart.

The consolidated multidistrict litigation names Kenvue—the Johnson & Johnson spinoff that now owns the Tylenol brand—as well as major retailers including CVS, Kroger, Target, Walgreens, and Walmart. The lawsuits allege that these companies failed to warn pregnant women about neurodevelopmental risks, despite a growing body of epidemiological studies suggesting a correlation. However, no definitive causal link has been established, and major medical organizations, including the American College of Obstetricians and Gynecologists, continue to recommend acetaminophen as the first-line treatment for pain and fever during pregnancy. The litigation has been shadowed by political posturing: in 2025, President Donald Trump and senior Department of Health and Human Services officials publicly suggested a connection between acetaminophen and autism, injecting further uncertainty into the scientific and regulatory landscape.

The financial stakes are significant. Kenvue, with a market capitalization near $40 billion, faces potential liabilities that could parallel the multi-billion-dollar settlements in the opioid or talc litigations. The company's statement, emphasizing that 'credible, independent science shows no proven link,' signals a vigorous defense. Retailers, meanwhile, could be exposed for pharmacy-chain labeling practices. The revival of these lawsuits may pressure Kenvue to settle or add warning labels, which would disrupt a $3 billion global acetaminophen market and erode consumer trust in one of the most widely used OTC medications.